SLC5A2 and Alzheimer disease: The demonstration that Enavogliflozin can modulate cholinergic signaling, similar to other SGLT2 inhibitors, suggests shared molecular targets with traditional FDA‐approved AD treatments (Khamies et al. 2024; Pang et al. 2023).